Arrowhead Pharmaceuticals Reports 2024 Fiscal Year-End Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/29/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- BioNTech ends colorectal cancer mRNA therapy trial early
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Pinterest CFO resigns, interim replacement named
Chardan Capital Markets Reiterates Buy Rating on Arrowhead Pharma (ARWR)
November 27, 2024 7:14 AM ESTChardan Capital Markets analyst Keay Nakae reiterated a Buy rating and $60.00 price target on Arrowhead Pharma (NASDAQ: ARWR).
The analyst comments "Arrowhead has announced a new global licensing and collaboration agreement with Sarepta Therapeutics (unrated). We believe that this is a positive development for... More
